Excision BioTherapeutics’ attempt to gene edit HIV disappoints. The company will now revamp vector: #ASGCT24

BAL­TI­MORE — HIV pa­tients who re­ceived a CRISPR-based gene edit­ing treat­ment de­vel­oped by Ex­ci­sion Bio­Ther­a­peu­tics saw the virus re­bound, and now the com­pa­ny is go­ing back to the lab to de­vel­op the ex­per­i­men­tal treat­ment with a new vec­tor.

In Ex­ci­sion’s Phase 1 study, five pa­tients re­ceived a gene edit­ing ther­a­py for HIV. Three pa­tients were tak­en off their stan­dard an­ti­retro­vi­ral ther­a­py, but then had to re­turn to stan­dard treat­ments, ac­cord­ing to clin­i­cal tri­al re­sults shared Fri­day at the Amer­i­can So­ci­ety of Gene & Cell Ther­a­py’s an­nu­al meet­ing in Bal­ti­more.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.